

Technology Advisory Committee A Interests Register

Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

Publication Date: 19 June 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Patrick De Barr	Committee A Member	Direct – financial interests	<p>The company Patrick works for has a PD1 antibody at late stage development but in a different indication. This has been declared at previous meetings.</p> <p>Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication.</p>	<p>12/03/2024</p> <p>25/01/2024</p>	It was agreed that Patrick's declaration would not prevent him from being part of the committee.